Trial Profile
A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Entinostat (Primary)
- Indications Brain metastases; Lymphoma; Solid tumours
- Focus Adverse reactions
- 14 Mar 2012 Additional lead trial centres added as reported by ClinicalTrials.gov.
- 14 Mar 2012 Additional lead trial centres added as reported by ClinicalTrials.gov.
- 06 Sep 2005 New trial record.